Background: Whether triple antiplatelet strategy is superior or similar to dual antiplatelet strategy in diabetic patients (pts) with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) remains unclear. Methods:2,074 diabetic pts with AMI underwent PCI with DES received either dual (aspirin plus clopidogrel, Dual group, n=1,220) or triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol, Triple group, n=854). Results: Triple group was associated with significantly lower incidence of total death and total MACE up to 8 months compared with Dual group (Table). Conclusions: The triple antiplatelet therapy appears to be superior to the conventional dual antiplatelet therapy in reducing early mortality and MACE without increasing the major bleeding in diabetic AMI pts undergoing PCI with DES.